Loading stock data…
$0.77-0.02 (-2.56%)
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Akebia Therapeutics, Inc. in the Healthcare sector is trading at $0.77 with a market capitalization of $272M. Wall Street consensus targets $3.92 (6 analysts), implying a +408.7% move over the next 12 months. The stock is currently near its 52-week low of $0.77, remaining 35.8% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $49.13M↓ | $53.54M↓ | $57.62M↓ | $58.77M↓ | $62.47M |
| Gross Profit | $38.70M↓ | $41.25M↓ | $45.09M↓ | $49.38M↓ | $52.55M |
| Operating Income | -$4.38M↑ | -$4.70M↑ | -$8.55M↓ | $4.45M↓ | $14.09M |
| Net Income | -$8.91M↑ | -$9.05M↑ | -$12.24M↓ | $540,000↑ | $247,000 |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hy...